Jan 07

A phase 2b trial of CER–001 (Cerenis Therapeutics)

A phase 2b trial of CER–001 (Cerenis Therapeutics), an engineered complex of recombinant human apolipoprotein A1 (apoA1) (the major structural protein of HDL), has failed to show that the agent can reduce total atheroma volume in patients with acute coronary syndrome (ACS). CER–001 is intended to mimic natural, nascent HDL (also known as pre–beta HDL) and to transiently increase apoA1 and the number of HDL particles to accelerate reverse lipid transport.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>